Targeting FLT3 to treat leukemia
Introduction: Approximately 23% of acute myeloid leukemia (AML) patients younger than 60 years of age carry a mutation in the transmembrane domain of the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/internal tandem duplications [ITD]). In normal karyotype AML, the presence of a FLT3/ITD mutation is...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Revisão |
| Lenguaje: | inglés |
| Publicado: |
2014
|
| Acceso en línea: | https://doi.org/10.1517/14728222.2014.960843 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|